Nasdaq:US$16.81 (+0.49) | HKEX:HK$26.70 (+0.30) | AIM:£2.57 (+0.02)
News & Presentations
Previous Article   |   Next Article
Presentations, Scientific Publications | 3 Jun 2014

ASCO 2014: A phase 1b study of VEGFR inhibitor fruquintinib in patients with pretreated advanced colorectal cancer